In 2002, the Blue Ribbon Panel established the research priorities for biodefense, including the prioritization of pathogens and the development of broad spectrum therapeutics to combat infections. This included two central themes: 1) the development of research capacity for organisms requiring high containment laboratories and 2) the centralization of research focus in the ten federally designated regions. In Region VII Washington University directs the Midwest Regional Center of Excellence for Biodefense and Emerging Infectious Disease Research (MRCE). Laboratory expansion in region VII occurred at the University of Missouri and the NIAID Regional Biocontainment Laboratory (RBL). In this proposal we describe the alignment of research goals and activities between the MRCE and RBL through the establishment of an Innate Immunity Core at the University of Missouri. Research Projects in the MRCE have a common theme to understand mechanisms of immune responses to priority pathogens, and participating researchers from five institutions collaborate to further this frontier. The MU RBL provides state of the art containment design and engineering as well as centralized resources and education for infectious disease research. Through the Innate Immunity Core (IIC) we will create experimental opportunities requiring access to live cell sorting and other immunological techniques on infected samples. Moreover, the IIC and the RBL are strucutred to permit flexibility and adaptation to the changing frontier of infectious disease research. Thus, the IIC provides a unique capability in region VII that creates opportunities for novel scientific achievements that further the research mission of the MRCE.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Specialized Center--Cooperative Agreements (U54)
Project #
5U54AI057160-10
Application #
8446490
Study Section
Special Emphasis Panel (ZAI1-DDS-M)
Project Start
2013-03-01
Project End
2014-02-28
Budget Start
2013-03-01
Budget End
2014-02-28
Support Year
10
Fiscal Year
2013
Total Cost
$93,026
Indirect Cost
$23,821
Name
Washington University
Department
Type
DUNS #
068552207
City
Saint Louis
State
MO
Country
United States
Zip Code
63130
Chen, Linxiao; Valentine, Jenny L; Huang, Chung-Jr et al. (2016) Outer membrane vesicles displaying engineered glycotopes elicit protective antibodies. Proc Natl Acad Sci U S A 113:E3609-18
Ulland, Tyler K; Jain, Nidhi; Hornick, Emma E et al. (2016) Nlrp12 mutation causes C57BL/6J strain-specific defect in neutrophil recruitment. Nat Commun 7:13180
Miao, Chunhui; Li, Minghua; Zheng, Yi-Min et al. (2016) Cell-cell contact promotes Ebola virus GP-mediated infection. Virology 488:202-15
Zhao, Jincun; Vijay, Rahul; Zhao, Jingxian et al. (2016) MAVS Expressed by Hematopoietic Cells Is Critical for Control of West Nile Virus Infection and Pathogenesis. J Virol 90:7098-108
Lubman, Olga Y; Fremont, Daved H (2016) Parallel Evolution of Chemokine Binding by Structurally Related Herpesvirus Decoy Receptors. Structure 24:57-69
Markosyan, Ruben M; Miao, Chunhui; Zheng, Yi-Min et al. (2016) Induction of Cell-Cell Fusion by Ebola Virus Glycoprotein: Low pH Is Not a Trigger. PLoS Pathog 12:e1005373
Grinnage-Pulley, Tara; Mu, Yang; Dai, Lei et al. (2016) Dual Repression of the Multidrug Efflux Pump CmeABC by CosR and CmeR in Campylobacter jejuni. Front Microbiol 7:1097
Teijaro, John R; Studer, Sean; Leaf, Nora et al. (2016) S1PR1-mediated IFNAR1 degradation modulates plasmacytoid dendritic cell interferon-α autoamplification. Proc Natl Acad Sci U S A 113:1351-6
Grinnage-Pulley, Tara; Zhang, Qijing (2015) Genetic Basis and Functional Consequences of Differential Expression of the CmeABC Efflux Pump in Campylobacter jejuni Isolates. PLoS One 10:e0131534
Nukui, Masatoshi; Mori, Yasuko; Murphy, Eain A (2015) A human herpesvirus 6A-encoded microRNA: role in viral lytic replication. J Virol 89:2615-27

Showing the most recent 10 out of 325 publications